Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...
More »SEARCH RESULT
Total Matching Records found : 78
Pratibha's Foreign Trips cost nation a record Rs. 205 crore
-PTI President Pratibha Patil's foreign visits have cost the public exchequer Rs. 205 crore, surpassing the record of all her predecessors. Since assuming office as the country's first woman President in July 2007, Ms. Patil has undertaken 12 trips covering 22 countries across four continents. She has four more months to go in her five-year tenure and a trip to South Africa is said to be on the anvil. A series of RTI...
More »President Patil's Foreign Trips cost record Rs 205 cr
-Rediff.com President Pratibha Patil's wanderlust has cost the public exchequer a whopping Rs 205 crore on her foreign visits, surpassing the record of all her predecessors. Since assuming office as the country's first woman President in July 2007, Patil has undertaken 12 Foreign Trips covering 22 countries across four continents. She has four more months to go for her five-year tenure and a trip to South Africa is said to be on...
More »'Maoists irked by Italians taking objectionable pictures of tribals'-Sandeep Mishra & Vishwa Mohan
In the first instance of Maoists targeting foreigners, two Italian tourists were abducted in the forests bordering Orissa's Kandhamal-Ganjam districts. The kidnapping came to light late on Saturday night after the Maoists released two men abducted along with the Italians, Bosusco Paolo and Claudio Colangelo. The Maoists claim the four were kidnapped on March 14. This came to light only after the release of Sontosh Moharana and Kartik Parida with audio...
More »Novartis vs India: the showdown approaches by Simon Reid-Henry
The Swiss-based pharmaceutical giant Novartis is taking the state of India to court in a case that has, after rumbling about in the lower courts for six years, wound up as a very public litmus test of the legal framework sustaining India’s generic drugs revolution. With the case due before the Supreme Court on 28 March, the fate of millions who depend on affordable Indian medicines may soon hang in the...
More »
